Handelsbanken Fonder Ab Karuna Therapeutics, Inc. Transaction History

Handelsbanken Fonder Ab

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 01, 2024	BUY	$161.01 - $317.85 $209,313 - $413,205	1,300 Added 22.81%	7,000 $2.22 Million
Q3 2023 Oct 19, 2023	BUY	$164.66 - $218.08 $98,796 - $130,848	600 Added 11.76%	5,700 $964,000
Q2 2023 Aug 02, 2023	BUY	$176.32 - $240.22 $229,216 - $312,286	1,300 Added 34.21%	5,100 $1.11 Million
Q3 2022 Oct 27, 2022	BUY	$123.79 - $277.42 $49,516 - $110,968	400 Added 11.76%	3,800 $855,000
Q1 2022 May 11, 2022	SELL	$98.9 - $132.37 $187,910 - $251,503	-1,900 Reduced 35.85%	3,400 $431,000
Q4 2021 Feb 08, 2022	SELL	$110.64 - $159.4 $33,192 - $47,820	-300 Reduced 5.36%	5,300 $694,000
Q3 2021 Nov 10, 2021	BUY	$101.2 - $125.87 $131,560 - $163,631	1,300 Added 30.23%	5,600 $685,000
Q2 2021 Aug 03, 2021	BUY	$107.45 - $135.95 $64,470 - $81,570	600 Added 16.22%	4,300 $490,000
Q4 2020 Feb 11, 2021	BUY	$75.23 - $109.23 $278,351 - $404,151	3,700 New	3,700 $376,000
Q3 2020 Nov 13, 2020	SELL	$71.31 - $109.74 $156,882 - $241,428	-2,200 Closed	0 $0
Q2 2020 Aug 13, 2020	BUY	$62.14 - $117.21 $136,708 - $257,862	2,200 New	2,200 $245,000

332K

Ticker KRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 33,965,000
Description
Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate is KarXT, an oral modulator of muscarinic receptors that is in Phase III clinical trial for the treatment of acute psychosis in patients wi...

Get notified when there are updates to the investment portfolio of Handelsbanken Fonder Ab, based on Form 13F filings with the SEC.

Stay updated on Handelsbanken Fonder Ab with notifications on news.